Neal J Meropol

20020031515, Mar 14, 2002

May 14, 2001

09/855342

Michael Caligiuri - Columbus OH, US
Neal Meropol - Jenkintown PA, US
Richard Schilsky - LaGrange IL, US

A01N037/18
A61K038/00
A61K045/00
A61K039/395
C07K001/00
C07K014/00
C07K017/00
C07K016/00
C12P021/08

424/155100, 530/387100, 530/388850, 514/002000, 514/012000, 530/350000, 424/156100

Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.

20080159981, Jul 3, 2008

Aug 2, 2007

11/888699

Michael A. Caligiuri - Columbus OH, US
Neal J. Meropol - Jenkintown PA, US
Richard L. Schilsky - LaGrange IL, US

A61K 38/20
A61P 35/00

424 852

Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.

20200272919, Aug 27, 2020

Feb 25, 2020

16/800715

- New York NY, US
Shrujal Baxi - Rye NY, US
Neal Meropol - Brooklyn NY, US
Geetu Ambwani - New York NY, US
Daniel Backenroth - New York NY, US
Mahesh Murali - New York NY, US
Andrej Rosic - New York NY, US
Chengsheng Jiang - Jersey City NJ, US

Flatiron Health, Inc. - New York NY

G06N 5/04
G16H 10/60
G16H 50/50
G16H 10/20
G16H 50/70
G06N 5/02
G06N 20/00

A model-assisted system for predicting survivability of a patient may include at least one processor. The processor may be programmed to access a database storing a medical record for the patient. The medical record may include at least one of structured and unstructured information relative to the patient and may lack a structured patient ECOG score. The processor may be further programmed to analyze at least one of the structured and unstructured information relative to the patient; based on the analysis, and in the absence of a structured ECOG score, generate a performance status prediction for the patient; and provide an output indicative of the predicted performance status. The analysis of at least one of the structured and unstructured information and the generation of the predicted performance status may be performed by at least one of a trained machine learning model or a natural language processing algorithm.

20200176127, Jun 4, 2020

Dec 3, 2019

16/702113

- New York NY, US
James Tyler Martineau - New York NY, US
Vivien Liu Ekuan - Los Altos CA, US
Dominique Connolly - Jersey City NJ, US
Neal J. Meropol - New York NY, US
Robert Jeffrey Green - West Palm Beach FL, US
Alison Fugaro - Atlanta GA, US
Helaina Talcott - New York NY, US
Amila Meera Patel - Seattle WA, US
Michael Tyler Haydell - New York NY, US
Kyle Ritter - College Station TX, US

Flatiron Health, Inc. - New York NY

G16H 70/20
G16H 70/40
G16H 10/60
G06F 16/338
G06F 3/048

A system for providing guideline concordance may include at least one processing device programmed to receive, via a graphical user interface of a user device, a search term associated with a drug; access a structured database to identify, based on the search term, a description of at least one regimen that includes the search term; display, via the graphical user interface, a selectable identifier of the at least one regimen; receive, via the graphical user interface, a selection of a regimen, wherein the regimen is associated with the drug; generate, based on the structured database, one or more indications that are concordant for the regimen; receive, via the graphical user interface, a selection of a concordant indication; and store, in an electronic health record database, a patient record with information identifying the selected regimen and the selected indication.

20160196411, Jul 7, 2016

Jan 5, 2016

14/988132

- Cleveland OH, US
Shiqiang Tao - Cleveland OH, US
Licong Cui - Cleveland OH, US
Neal J. Meropol - Shaker Heights OH, US

G06F 19/00
H04L 29/06

Systems and methods for matching of patients with clinical trials are described herein. The matching can be performed in an automated fashion and integrated with an existing clinical workflow. Patient data can be retrieved from an existing clinical data management system. The patient data can be evaluated against eligibility criteria for a plurality of clinical trials to determine an eligibility of the patient for each of the plurality of clinical trials. Results corresponding to the eligibility of the patient for each of the plurality of clinical trials can be displayed on a graphical user interface.